全文获取类型
收费全文 | 18009篇 |
免费 | 1649篇 |
国内免费 | 1235篇 |
专业分类
耳鼻咽喉 | 255篇 |
儿科学 | 226篇 |
妇产科学 | 174篇 |
基础医学 | 2193篇 |
口腔科学 | 394篇 |
临床医学 | 2350篇 |
内科学 | 2509篇 |
皮肤病学 | 140篇 |
神经病学 | 908篇 |
特种医学 | 740篇 |
外国民族医学 | 13篇 |
外科学 | 1704篇 |
综合类 | 3316篇 |
现状与发展 | 4篇 |
一般理论 | 1篇 |
预防医学 | 1170篇 |
眼科学 | 466篇 |
药学 | 1916篇 |
23篇 | |
中国医学 | 974篇 |
肿瘤学 | 1417篇 |
出版年
2024年 | 67篇 |
2023年 | 322篇 |
2022年 | 755篇 |
2021年 | 965篇 |
2020年 | 715篇 |
2019年 | 634篇 |
2018年 | 638篇 |
2017年 | 620篇 |
2016年 | 562篇 |
2015年 | 842篇 |
2014年 | 1064篇 |
2013年 | 906篇 |
2012年 | 1322篇 |
2011年 | 1481篇 |
2010年 | 859篇 |
2009年 | 740篇 |
2008年 | 916篇 |
2007年 | 876篇 |
2006年 | 944篇 |
2005年 | 890篇 |
2004年 | 619篇 |
2003年 | 531篇 |
2002年 | 515篇 |
2001年 | 391篇 |
2000年 | 404篇 |
1999年 | 483篇 |
1998年 | 303篇 |
1997年 | 296篇 |
1996年 | 211篇 |
1995年 | 199篇 |
1994年 | 149篇 |
1993年 | 101篇 |
1992年 | 105篇 |
1991年 | 92篇 |
1990年 | 83篇 |
1989年 | 68篇 |
1988年 | 56篇 |
1987年 | 36篇 |
1986年 | 40篇 |
1985年 | 37篇 |
1984年 | 25篇 |
1983年 | 11篇 |
1982年 | 6篇 |
1981年 | 5篇 |
1980年 | 2篇 |
1979年 | 6篇 |
1976年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Zeyu Li Erwei Hao Rui Cao Si Lin Linghui Zou Tianyan Huang Zhengcai Du Xiaotao Hou Jiagang Deng 《中草药(英文版)》2022,14(4):479-493
Zedoary tumeric (Curcumae Rhizoma, Ezhu in Chinese) has a long history of application and has great potential in the treatment of liver cancer. The anti liver cancer effect of zedoary tumeric depends on the combined action of multiple pharmacodynamic substances. In order to clarify the specific mechanism of zedoary tumeric against liver cancer, this paper first analyzes the mechanism of its single pharmacodynamic substance against liver cancer, and then verifies the joint anti liver cancer mechanism of its "pharmacodynamic group". By searching the research on the anti hepatoma effect of active components of zedoary tumeric in recent years, we found that pharmacodynamic substances, including curcumol, zedoarondiol, curcumenol, curzerenone, curdione, curcumin, germacrone, β-elemene, can act on multi-target and multi-channel to play an anti hepatoma role. For example, curcumin can regulate miR, GLO1, CD133, VEGF, YAP, LIN28B, GPR81, HCAR-1, P53 and PI3K/Akt/mTOR, HSP70/TLR4 and NF-κB. Wnt/TGF/EMT, Nrf2/Keap1, JAK/STAT and other pathways play an anti hepatoma role. Network pharmacological analysis showed that the core targets of the "pharmacodynamic group" for anti-life cancer are AKT1, EGFR, MAPK8, etc, and the core pathways are neuroactive live receiver interaction, nitrogen metabolism, HIF-1 signaling pathway, etc. At the same time, by comparing and analyzing the relationship between the specific mechanisms of pharmacodynamic substance and "pharmacodynamic group", it is found that they have great reference significance in target, pathway, biological function, determination of core pharmacodynamic components, formation of core target protein interaction, in-depth research of single pharmacodynamic substance, increasing curative effect and so on. By analyzing the internal mechanism of zedoary tumeric pharmacodynamic substance and "pharmacodynamic group" in the treatment of liver cancer, this paper intends to provide some ideas and references for the deeper pharmacological research of zedoary tumeric and the relationship between pharmacodynamic substance and "pharmacodynamic group". 相似文献
2.
Clinical and Experimental Medicine - Recently, the use of novel targeted drugs significantly improved the overall response rate (ORR) and survival of patients with relapsed/refractory chronic... 相似文献
3.
目的 探讨不同年龄阿尔茨海默病(AD)患者ADC值与年龄的相关性。方法 选取30例AD患者(AD组)和年龄与之相匹配的30名志愿者(对照组),按年龄段各分为6个亚组[55~59岁(n=3)、60~64岁(n=4)、65~70岁(n=9)、71~74岁(n=5)、75~80岁(n=6)、>80岁(n=3)],测量双侧海马、红核、尾状核、杏仁体、壳核ADC值,并进行配对t检验、独立样本t检验、单因素方差分析及Pearson相关分析。结果 AD组红核左、右侧ADC值有统计学差异(P=0.022)。AD组不同年龄亚组右侧海马、双侧尾状核、右侧壳核ADC值差异有统计学意义(P均<0.05);2组不同年龄亚组双侧海马、壳核、尾状核ADC值差异有统计学意义(P均<0.05)。AD组右侧海马(r=0.615,P<0.001)、右侧壳核(r=0.653,P=0.001)及双侧尾状核(左侧:r=0.397,P=0.030;右侧:r=0.429,P=0.020)ADC值与年龄呈正相关。结论 AD患者右侧海马和壳核、双侧尾状核ADC值随年龄增加而增大。ADC值可为临床预测和早期诊断AD脑内右侧海马和壳核、双侧尾状核神经退行性病变提供参考。 相似文献
4.
5.
6.
7.
Haochu Li Xiaoming Li Lai Sze Tso Shan Qiao Eleanor Holroyd Yuejiao Zhou 《Vulnerable children and youth studies》2016,11(2):173-179
In HIV/AIDS research, few studies to date have evaluated ways to improve parental HIV disclosure practices using feedback from HIV-negative children who have recently experienced this event. We conducted semi-structured in-depth interviews with 20 children (aged 6–15) who were partially to fully aware of their parents’ HIV status in rural Guangxi, China. Of the 20 children, eight children who were of older age (11.38 years in average) endorsed parental HIV disclosure, five discouraged it and seven expressed uncertainty. Children’s different experiences and attitudes towards disclosure were seen to be associated with their family dynamics (especially the parent–child relationship), social support and care, experiences of stigma and discrimination, psychosocial suffering, comprehension of the disease and the children’s age. Our study contributes to building a child-centered comprehensive understanding for Chinese parental HIV disclosure. It is imperative that counselors and community advocates assess and help parents achieve optimal readiness preceding disclosure of their illness to their HIV-negative children. 相似文献
8.
9.
10.
Ju Zou Daichao Wu Tao Li Xianwen Wang Yan Liu Sijie Tan 《Pathology, research and practice》2019,215(2):229-234
Programmed death ligand 1(PD-L1) mediated immune escape play important roles in the development of cancer. The gene polymorphism of PD-L1, in particular rs4143815 C?>?G, has been associated with the cancer risks, but with conflicting results. Therefore, this meta-analysis was aimed to assess the association between rs4143815 C?>?G and cancer susceptibility. A systematic literature search was performed to select the studies and the pooled odds ratio (OR) with 95% confidence interval (CI) was used to evaluate the strength of association. Eleven eligible studies containing 3711 cases and 3704 controls were enrolled in the meta-analysis. The results suggested that there is a strong association between rs4143815 C?>?G and the cancer risks (G vs. C: OR?=?1.386, 95% CI: 1.132–1.696, p?=?0.002; GG vs. CG?+?CC: OR?=?1.843 95% CI: 1.300–2.613, p?=?0.002; GG?+?CG vs. CC: OR?=?1.280, 95% CI: 1.040–1.576, p?=?0.020). Subgroup analysis based on cancer type suggested that PD-L1 rs4143815 C?>?G might increase the susceptibility to gastric cancer (G vs. C: OR?=?1.842, 95% CI: 1.403–2.418, p?<?0.001) and bladder cancer (G vs. C: OR?=?2.015, 95% CI: 1.556–2.608, p?<?0.001), and genotype GG carriers of PD-L1 rs4143815 C?>?G might have higher risks of HCC (GG vs. CG?+?CC: OR?=?2.226 95% CI: 1.562–3.172, p?<?0.001). PD-L1 rs4143815 C?>?G might confer an increased cancer risk, indicating this SNP may contribute to the pathogenesis of cancer and might be used as a potential biomarker to predict the susceptibility to cancer. 相似文献